LRMR
NASDAQ · Biotechnology
Larimar Therapeutics Inc
$4.73
+0.23 (+5.11%)
Financial Highlights (FY 2025)
Revenue
175.11M
Net Income
-19,494,630
Gross Margin
63.2%
Profit Margin
-11.1%
Rev Growth
-5.1%
D/E Ratio
0.69
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 63.2% | 63.2% | 63.2% |
| Operating Margin | -12.2% | -13.1% | -13.4% |
| Profit Margin | -11.1% | -10.5% | -11.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 175.11M | 171.92M | 184.32M |
| Gross Profit | 110.74M | 108.72M | 116.56M |
| Operating Income | -21,324,164 | -22,440,768 | -24,653,380 |
| Net Income | -19,494,630 | -18,016,562 | -21,970,966 |
| Gross Margin | 63.2% | 63.2% | 63.2% |
| Operating Margin | -12.2% | -13.1% | -13.4% |
| Profit Margin | -11.1% | -10.5% | -11.9% |
| Rev Growth | -5.1% | +17.2% | +14.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 116.92M | 97.87M | 111.57M |
| Total Equity | 169.45M | 168.38M | 165.86M |
| D/E Ratio | 0.69 | 0.58 | 0.67 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -28,814,403 | -28,168,357 | -29,490,113 |
| Free Cash Flow | -20,989,250 | -18,411,143 | -19,560,158 |